Warburg Pincus to invest Can$35 million in Protox to get BPH treatment to market
This article was originally published in Scrip
Executive Summary
Warburg Pincus is to invest up to Can$35 million ($34 million) in publicly held Protox Therapeutics to provide the Canadian firm with the financial resources to pursue its lead programme, PRX302 for the treatment of benign prostatic hyperplasia (BPH), through to regulatory approval.